Mercury Biopharmaceutical Corporation (TPEX:6932)
Taiwan · Delayed Price · Currency is TWD 9.12
-0.47 (-4.90%)
Jan 22, 2026, 1:04 PM CST
Mercury Biopharmaceutical Revenue
Mercury Biopharmaceutical had revenue of 246.00K TWD in the twelve months ending June 30, 2025, down -95.72% year-over-year. In the year 2024, Mercury Biopharmaceutical had annual revenue of 4.96M with 380.45% growth.
Revenue (ttm)
246.00K
Revenue Growth
-95.72%
P/S Ratio
16,312.51
Revenue / Employee
n/a
Employees
n/a
Market Cap
4.01B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.96M | 3.93M | 380.45% |
| Dec 31, 2023 | 1.03M | -1.65M | -61.46% |
| Dec 31, 2022 | 2.68M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Formosa Laboratories | 4.90B |
| Orient EuroPharma | 4.53B |
| Maywufa Company | 1.55B |
| SCI Pharmtech | 1.39B |
| Orient Pharma | 1.28B |
| Allied Biotech | 821.81M |
| Easywell Biomedicals | 588.89M |
| Johnson Chemical Pharmaceutical Works | 567.06M |